Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Sponsor: Verastem, Inc.
Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Official title: A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
225
Start Date
2020-12-21
Completion Date
2026-12
Last Updated
2025-01-29
Healthy Volunteers
No
Interventions
avutometinib (VS-6766)
avutometinib (VS-6766) monotherapy
avutometinib (VS-6766) and defactinib
avutometinib (VS-6766) and defactinib combination
Locations (47)
Arizona Oncology Associates PC HAL
Scottsdale, Arizona, United States
Sansum Clinic
Santa Barbara, California, United States
Yale School of Medicine
New Haven, Connecticut, United States
Advent Health
Orlando, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
Maryland Oncology and Hematology, P.A.
Glenn Dale, Maryland, United States
Minnesota Oncology Hematology PA
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Cleveland Clinic Women's Health Institute
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
University of Oklahoma Medical Center
Oklahoma City, Oklahoma, United States
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
Northwest Cancer Specialists
Portland, Oregon, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Texas Oncology Austin Central
Austin, Texas, United States
Texas Oncology- Dallas Presbyterian Hospital
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Texas Oncology
Longview, Texas, United States
Texas Oncology
McAllen, Texas, United States
Texas Oncology
San Antonio, Texas, United States
Texas Oncology
The Woodlands, Texas, United States
University of Virginia Health System
Charlottesville, Virginia, United States
Virginia Cancer Specialists, PC
Gainesville, Virginia, United States
UZ Gent Medische Oncologie
Ghent, Belgium
UZ Leuven
Leuven, Belgium
CHU de Liege
Liège, Belgium
Centre de recherche di Centre Hospitalier de i'Universite de Montreal
Montreal, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Hopital Jean Minjoz
Besançon, France
Centre Leon Berard
Lyon, France
ICM - Val d'Aurelle
Montpellier, France
Institut Curie
Paris, France
Insituto Europeo di Oncologia I.R.C.C.S
Milan, Italy
U.O.C. Oncologia 2, Istituto Oncologico Veneto I.R.C.C.S.
Padova, Italy
Hospital Universitario Vall D'Hebron
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Western General Hospital
Edinburgh, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
UCLH Cancer Clinical Trials Unit
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom